Prof. Dr. Michael Rossbach is a seasoned life and health sciences professional, with expertise in immunology, cell-based therapeutics, neuroscience and genomics.Michael is the founder and Managing Partner of Ikxinta – Advisers in Health and Life Sciences (USA, Portugal, Germany, Singapore, China) and holds academic appointments at the National University of Singapore (NUS), at the Technical University of Munich (TUM Asia) in Singapore, at INSEAD Management School (Entrepreneur-in-Residence) and he is Prof. and a member of the Faculty of the Witten School of Management (Witten Group, Germany).Michael is an elected member of the Scientific Council of the Deutsches Elektronen-Synchrotron DESY, a research center of the Helmholtz Association (Germany’s largest accelerator and research center).Michael is an Associate with the Biotech Developpement Conseils in Paris, Partner of the Höppner Life Sciences Management Group (Germany), Partner of the healthcare team of The Center For Innovation Commercialization LLC (CICL) in the US, and a Venture Partner of Graybella Capital (USA) and A9C Capital (Bahrain). Michael serves on Scientific Advisory Boards and Boards of several biotech companies and on the Investment Committees of investment companies and family offices in Europe and Asia; he heads the life science section of Altaira Wealth Management (Geneva, Switzerland).Michael studied biochemistry at the University of Bonn (Germany), the University of New South Wales (Sydney, Australia), the University of Witten/Herdecke (Witten, Germany), the Max-Planck Institute for molecular Physiology (Dortmund, Germany) and at Harvard Medical School (Boston, USA), where he obtained his PhD in immunology. His scientific interest lies in complex gene regulation (particularly in non-coding RNAs), stem cell / regenerative biology, and in tumor-immunobiology.